Skip to main content

Market Overview

Twist Bioscience Launches Methylation Detection Systems

  • Twist Bioscience Corp (NASDAQ: TWST) has launched its NGS Methylation Detection System, end-to-end sample preparation, and target enrichment solution for identifying methylated regions in the human genome.
  • DNA methylation plays a key role in many biological processes, including cancer. A methyl group can alter genetic behavior without changing the DNA sequence when present on a single nucleotide.
  • In cancer methylation, patterns appear early, providing an approach for screening through liquid biopsy tests designed to detect a wide range of tumors from a single blood sample.
  • Also, Twist has partnered with New England Biolabs (NEB), which have developed an enzyme-based alternative to sodium bisulfite treatment, EM-seqTM, for the preparation of samples for methylation analysis.
  • Earlier this week, Twist Bioscience and China's Berry Genomics announced a partnership on next-generation sequencing target enrichment and library preparation tools.
  • Price Action: TWST is up 2.02% at $138.02 in market trading hours on the last check Wednesday.

Related Articles (TWST)

View Comments and Join the Discussion!

Posted-In: cancerNews Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at